30 Apr Exact Sciences reports 79% jump in Cologuard test volume, first-quarter revenue
Exact Sciences Corp., the Madison-based maker of the Cologuard take-home colon cancer test and one of the largest public companies in Wisconsin, reported revenue of $162 million for its first quarter of 2019, along with test volume of approximately 334,000 for the period ending March 31.
The first quarter revenue and test volume numbers were 79% increases from the year-ago period, according to the quarterly report from the company.
Exact Sciences (Nasdaq: EXAS) is the fastest growing public company in Wisconsin, according to Milwaukee Business Journal research. The company has experienced three-year revenue growth of 357.31% from fiscal 2016 to fiscal 2018.
In its report, the company also indicated it has increased its guidance for fiscal 2019, anticipating revenue between $725 million and $740 million. The prior guidance for 2019 was for revenue between $710 million and $730 million.]
Sorry, the comment form is closed at this time.